UY29441A1 - Oblea que contiene hormonas esteroides - Google Patents

Oblea que contiene hormonas esteroides

Info

Publication number
UY29441A1
UY29441A1 UY29441A UY29441A UY29441A1 UY 29441 A1 UY29441 A1 UY 29441A1 UY 29441 A UY29441 A UY 29441A UY 29441 A UY29441 A UY 29441A UY 29441 A1 UY29441 A1 UY 29441A1
Authority
UY
Uruguay
Prior art keywords
steroid hormones
oblea
application system
film
containing steroid
Prior art date
Application number
UY29441A
Other languages
English (en)
Inventor
Markus Krume
Sascha General
Albert Radlmaier
Michael Dittgen
Keith Jensen
Original Assignee
Lts Lohmann Therapie Sisteme A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36998911&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY29441(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lts Lohmann Therapie Sisteme A filed Critical Lts Lohmann Therapie Sisteme A
Publication of UY29441A1 publication Critical patent/UY29441A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34—Gestagens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/40—Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/44—Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La invención se refiere a una composición farmacvéutica como un sistema en forma de película para la administración transmucular de hormonas esteroides. Se divulga un sistema de aplicación que se sisuelve en la cavidad bucal para hormonas esteroides que se libera con una elevada ciodisponibilidad. El sistema de aplicación en forma de película se disuelve en la cavidad bucal, con preferencia, un un período de menos de 30 min, en donde la homona esteroide del sistema de aplicación que penetra por via trnsmucosa en la circulación sanguínea produce un rápido aumento de la concentración en la sangre.
UY29441A 2005-03-31 2006-03-27 Oblea que contiene hormonas esteroides UY29441A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102005015128A DE102005015128B4 (de) 2005-03-31 2005-03-31 Wafer enthaltend Steroidhormone

Publications (1)

Publication Number Publication Date
UY29441A1 true UY29441A1 (es) 2006-10-31

Family

ID=36998911

Family Applications (1)

Application Number Title Priority Date Filing Date
UY29441A UY29441A1 (es) 2005-03-31 2006-03-27 Oblea que contiene hormonas esteroides

Country Status (26)

Country Link
US (2) US9763960B2 (es)
EP (1) EP1863444B1 (es)
JP (2) JP5843416B2 (es)
KR (2) KR101428625B1 (es)
CN (2) CN101132766A (es)
AR (1) AR054245A1 (es)
AU (1) AU2006228820B2 (es)
BR (1) BRPI0609601A2 (es)
CA (1) CA2598892C (es)
CR (1) CR9468A (es)
DE (1) DE102005015128B4 (es)
DO (1) DOP2006000070A (es)
EA (1) EA014183B1 (es)
GT (1) GT200600126A (es)
IL (1) IL186081A0 (es)
MX (1) MX2007012081A (es)
NO (1) NO20075404L (es)
NZ (1) NZ592882A (es)
PE (1) PE20061194A1 (es)
SG (1) SG179459A1 (es)
SV (1) SV2008002466A (es)
TW (1) TWI393576B (es)
UA (1) UA92011C2 (es)
UY (1) UY29441A1 (es)
WO (1) WO2006102990A2 (es)
ZA (1) ZA200706116B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2985026B1 (en) 2005-04-15 2022-08-03 Clarus Therapeutics, Inc. Pharmaceutical delivery systems for hydrophobic drugs and compositions comprising same
US8492369B2 (en) 2010-04-12 2013-07-23 Clarus Therapeutics Inc Oral testosterone ester formulations and methods of treating testosterone deficiency comprising same
DE102006027796A1 (de) * 2006-06-16 2007-12-20 Lts Lohmann Therapie-Systeme Ag Estrogen-Gestagen-Kombinationen
JP2011511823A (ja) * 2008-02-13 2011-04-14 バイエル・シエーリング・ファーマ アクチエンゲゼルシャフト エストラジオール含有薬物の送達システム
MX2010008945A (es) * 2008-02-13 2010-09-07 Bayer Schering Pharma Ag Sistema de administracion de drogas con efecto estabilizante.
TW201008569A (en) * 2008-08-08 2010-03-01 Bayer Schering Pharma Ag Progestin-containing drug delivery system
CA2744127A1 (en) * 2008-11-21 2010-05-27 Bayer Schering Pharma Aktiengesellschaft Drug delivery system
DK3254676T3 (en) 2009-10-30 2019-03-11 Ix Biopharma Ltd QUICK-SOLVING SOLID DOSAGE FORM
US10806703B2 (en) * 2012-01-20 2020-10-20 Lts Lohmann Therapie-System Ag Transmucosal administration system for a pharmaceutical drug
US9822257B2 (en) 2012-07-23 2017-11-21 Crayola Llc Dissolvable films and methods of using the same
DE102017112527B4 (de) * 2017-06-07 2019-01-03 Lts Lohmann Therapie-Systeme Ag Schnell zerfallende Schaumwafer mit hohem Flächengewicht
MX2020008147A (es) * 2018-02-02 2020-10-28 Acerus Biopharma Inc Metodos de terapia de testosterona.

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB981372A (en) * 1960-05-04 1965-01-27 Pfizer Ltd Pharmaceutical formulations for oral administration to animals
US4136162A (en) * 1974-07-05 1979-01-23 Schering Aktiengesellschaft Medicament carriers in the form of film having active substance incorporated therein
US4764378A (en) * 1986-02-10 1988-08-16 Zetachron, Inc. Buccal drug dosage form
DE69312487T2 (de) * 1992-05-18 1997-11-27 Minnesota Mining & Mfg Einrichtung zur transmucosalen wirkstoffabgabe
DE19646392A1 (de) * 1996-11-11 1998-05-14 Lohmann Therapie Syst Lts Zubereitung zur Anwendung in der Mundhöhle mit einer an der Schleimhaut haftklebenden, Pharmazeutika oder Kosmetika zur dosierten Abgabe enthaltenden Schicht
DE19847252B4 (de) * 1998-10-02 2004-02-12 Jenapharm Gmbh & Co. Kg Bukkal applizierbare bioadhäsive Systeme mit zeitlich gesteuerter Wirkstofffreisetzung enthaltend Testosteronester und fakultativ zusätzlich Testosteron
US6552024B1 (en) * 1999-01-21 2003-04-22 Lavipharm Laboratories Inc. Compositions and methods for mucosal delivery
US6264981B1 (en) * 1999-10-27 2001-07-24 Anesta Corporation Oral transmucosal drug dosage using solid solution
US20030092658A1 (en) * 2001-02-02 2003-05-15 Meyers Rachel E. Novel human enzyme family members and uses thereof
CN1441669A (zh) * 2000-07-06 2003-09-10 德尔西斯药品公司 配制稳定性增强的保健产品的方法
GB0100760D0 (en) * 2001-01-11 2001-02-21 Biocompatibles Ltd Drug delivery from stents
US6585997B2 (en) * 2001-08-16 2003-07-01 Access Pharmaceuticals, Inc. Mucoadhesive erodible drug delivery device for controlled administration of pharmaceuticals and other active compounds
FR2832311B1 (fr) * 2001-11-21 2004-04-16 Besins Int Belgique Poudre filmogene, compositions la comprenant, leurs procedes de preparation et leurs utilisations
JO2492B1 (en) * 2003-04-28 2009-10-05 شيرينج ايه جي A pharmaceutical formula in the form of aqueous gel for the skin use of its active ingredients
US20050059645A1 (en) * 2003-07-31 2005-03-17 Bodor Nicholas S. Methods for the treatment of male and female sexual dysfunction
JP5619337B2 (ja) * 2003-10-10 2014-11-05 フェリング ビー．ブイ． 皮膚残渣を最小限に抑えるための経皮的医薬製剤

Also Published As

Publication number Publication date
DOP2006000070A (es) 2007-08-15
NO20075404L (no) 2007-12-20
JP2008534533A (ja) 2008-08-28
AU2006228820A1 (en) 2006-10-05
SV2008002466A (es) 2008-02-08
DE102005015128A1 (de) 2006-10-05
CN104983669B (zh) 2018-05-18
JP2013155190A (ja) 2013-08-15
AR054245A1 (es) 2007-06-13
KR20140063740A (ko) 2014-05-27
EA200702102A1 (ru) 2008-04-28
CA2598892C (en) 2014-10-14
CA2598892A1 (en) 2006-10-05
KR20080002798A (ko) 2008-01-04
DE102005015128B4 (de) 2008-12-11
MX2007012081A (es) 2007-11-21
EA014183B1 (ru) 2010-10-29
BRPI0609601A2 (pt) 2010-04-20
WO2006102990A2 (de) 2006-10-05
GT200600126A (es) 2007-03-14
TWI393576B (zh) 2013-04-21
JP5843416B2 (ja) 2016-01-13
TW200714299A (en) 2007-04-16
ZA200706116B (en) 2008-11-26
US9763960B2 (en) 2017-09-19
KR101428625B1 (ko) 2014-08-13
CN104983669A (zh) 2015-10-21
IL186081A0 (en) 2008-01-20
US20170348321A1 (en) 2017-12-07
CR9468A (es) 2008-01-21
EP1863444B1 (de) 2015-12-09
CN101132766A (zh) 2008-02-27
WO2006102990A3 (de) 2007-03-22
SG179459A1 (en) 2012-04-27
PE20061194A1 (es) 2006-11-23
UA92011C2 (ru) 2010-09-27
US20060222708A1 (en) 2006-10-05
NZ592882A (en) 2012-12-21
AU2006228820B2 (en) 2011-08-25
EP1863444A2 (de) 2007-12-12

Similar Documents

Publication Publication Date Title
UY29441A1 (es) Oblea que contiene hormonas esteroides
AR060306A1 (es) Terapia de combinacion de anticuerpos contra ctla4
AR049985A1 (es) Tratamiento de combinacion para enfermedades malignas no hematologicas
AR068185A1 (es) Composiciones de tabletas de desintegracion oral de lamotrigina
PH12015500407A1 (en) Methods of treating hypertriglyceridemia
AR065246A1 (es) Composiciones para mejorar la absorcion gastrointestinal de nutrientes y de farmacos
CO6670567A2 (es) Métodos de tratamiento contra el cáncer pancreático
AR057946A1 (es) Formulacion de zonisamida de liberacion sostenidda
GT201000182A (es) Regimen de dosificacion asociado con ésteres de paliperidona inyectables de acción prolongada
SV2011003828A (es) Anticuerpos monoclonales contra el inhibidor de la via del factor tisular (tfpi)
BR112013027674A2 (pt) "usos de composições de nanopartículas, composições compreendendo as referidas nanopartículas e cateter com uma agulha".
BR112014011841A2 (pt) material de entrega de fármacos hidrofóbicos, método para a produção do mesmo e métodos para a entrega de uma composição de entrega de fármacos
AR060836A1 (es) Un disco trans-mucosa para administrar un agente activo, una composicion trans-mucosa y el metodo de administracion obtenido
EA201001288A1 (ru) Лечение гипертонии 25-гидроксивитамином d3
EA200702522A1 (ru) Система доставки лекарств в полость рта и способы ее применения
EA200970374A1 (ru) Лечение антиаритмическими средствами и омега-3 жирными кислотами и их комбинированным продуктом
UY32821A (es) Cápsulas de liberación sostenida
ECSP14023048A (es) Agentes terapéuticos para administración subcutánea optimizados
DE602008006700D1 (es)
BR112012014107B8 (pt) sistema terapêutico transdérmico (tts) e processo de produção de tts
PE20081573A1 (es) Composiciones y metodos para tratar las convulsiones
CO6450623A2 (es) Parasiticidas sanguineos
BRPI0513186A (pt) composição medicinal para a administração oral
AR044675A1 (es) Metodo para el tratamiento de la esquizofrenia en un paciente con sobrepeso
CL2011000614A1 (es) Forma de dosificacion oral solida que comprende alisquireno solo o en combinacion con otro agente activo; proceso de preparacion; y uso en el tratamiento de enfermedades tales comohipertension, angina, ateroesclerosis, entre otras.

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20160810